We reported on the six Federal Court and three FCA PMNOC Regulations decisions publicly released in 2017: see summary table here. See also the Therapeutic Products Directorate report providing a statistical overview of Health Canada's administration of the PMNOC Regulations and data protection; and the Therapeutic Products Directorate and the Biologics and Genetic Therapies Directorate's Drug Submission Performance Annual Reports regarding drug submission review activity, including approval times.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
